Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction

Introduction: There is a paucity of data regarding the best practice to institute iv Daratumumab (D) in morbid obese patients regarding the infusion rate and duration, optimal dosing, and ideal way to cope with the infusion related reactions (IRR). We wanted to present the fi rst split dose D infusion experience in a morbid obese MM case whose D was interrupted because of a grade 3 IRR.